Eliason Jonathan L, Clouse W Darrin
Section of Vascular Surgery, Department of Surgery, The University of Michigan Health System, CVC 5463, 1500 E. Medical Center Drive, SPC 5867, Ann Arbor, MI 48109-5867, USA.
Surg Clin North Am. 2007 Oct;87(5):1017-33, viii. doi: 10.1016/j.suc.2007.08.002.
Since the concept of endovascular aneurysm repair (EVAR) was introduced more than 15 years ago, many technological advances and multiple generations of aortic stent-graft devices have been used to manage infrarenal abdominal aortic aneurysms. In this rapidly changing environment, the determination of the optimal management of patients with aneurysmal disease can be difficult. In this article, the current management of infrarenal abdominal aortic aneurysms is outlined. Consistent data revealing short-term advantages in morbidity and mortality make EVAR a very appealing option for practitioners and patients. However, mid- and long-term data proving an all-cause mortality benefit are lacking. Open repair has proven durability, and should be strongly considered in younger and lower-risk patients.
自15年多前血管内动脉瘤修复术（EVAR）的概念被提出以来，许多技术进步以及多代主动脉覆膜支架装置已被用于治疗肾下腹主动脉瘤。在这个快速变化的环境中，确定动脉瘤性疾病患者的最佳治疗方案可能会很困难。本文概述了目前肾下腹主动脉瘤的治疗方法。一致的数据显示，EVAR在短期发病率和死亡率方面具有优势，这使其对从业者和患者来说是一个非常有吸引力的选择。然而，缺乏证明全因死亡率获益的中长期数据。开放修复已被证明具有耐久性，对于年轻和低风险患者应强烈考虑。
